Idowu Abiodun, Adebolu Olayinka, Bruce Casipit, Nriagu Bede, Evbayekha Endurance, Lo Kevin Bryan, Afolabi-Brown Olayinka, Rangaswami Janani
Department of Medicine Einstein Medical Center, Philadelphia, Pennsylvania, USA.
Department of Medicine New York Medical College Metropolitan Hospital Center, New York City, New York, USA.
Cardiovasc Ther. 2024 May 27;2024:2735577. doi: 10.1155/2024/2735577. eCollection 2024.
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to lower incident heart failure (HF) and HF hospitalizations, but the mechanisms of benefit in relation to invasive hemodynamics remain unclear. Using PRISMA guidelines, we systematically reviewed multiple online databases for randomized trials evaluating the effect of SGLT2i on invasive hemodynamics. Rest and peak exercise invasive hemodynamics were measured via right heart catheterization pre- and postintervention. Random effects model meta-analysis at a 95% confidence interval was done using RevMan 5.0. A total of 3 studies with a total of 145 patients were included in the meta-analysis. SGLT2i was significantly associated with a reduction in pulmonary capillary wedge pressure at rest and peak exercise. Similarly, SGLT2i reduced mean pulmonary artery pressure at rest and peak exercise, respectively; however, this was not statistically significant. This hypothesis-generating study offers mechanistic insights into the central hemodynamic effects of SGLT2i underpinning the HF benefits of SGLT2i.
钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)已被证明可降低心力衰竭(HF)的发病率和HF住院率,但其与有创血流动力学相关的获益机制仍不清楚。我们使用PRISMA指南,系统检索了多个在线数据库,以查找评估SGLT2i对有创血流动力学影响的随机试验。在干预前后通过右心导管测量静息和运动峰值时的有创血流动力学。使用RevMan 5.0进行95%置信区间的随机效应模型荟萃分析。荟萃分析共纳入3项研究,总计145例患者。SGLT2i与静息和运动峰值时肺毛细血管楔压的降低显著相关。同样,SGLT2i分别降低了静息和运动峰值时的平均肺动脉压;然而,这在统计学上并不显著。这项产生假设的研究为SGLT2i的中心血流动力学效应提供了机制性见解,这些效应是SGLT2i对HF有益作用的基础。